GE touts DaTscan study results
Article Thumbnail ImageJune 20, 2012 -- GE Healthcare is touting the results of a randomized, controlled study that found its contrast agent DaTscan (ioflupane I-123 injection) to be useful in SPECT imaging of adult patients with clinically uncertain Parkinsonian syndromes (CUPS).
Member Sign In:
  MemberID or E-mail Address:

New Members

Becoming a Member is FREE!

  • Real-time radiology-specific news
  • Case of the Day and Teaching Files
  • Focused topics digital communities
  • Lively, discussion groups
  • Medical imaging bookstore
  • SalaryScan
  • Job Boards
  • Online CME
  • Bookstore, market reports, more …
  • Conference Calendar
  • User-controlled eNewsletters
  • … registration is FREE and easy!
  • The findings from the multicenter trial in the U.S. and Europe showed significant differences in change in clinical management, diagnosis, and physician confidence of diagnosis for a group of patients with CUPS who had been imaged with DaTscan, according to the vendor.

    The study analyzed 135 subjects who received DaTscan imaging, comparing them against 138 healthy individuals who did not. Researchers evaluated patients at four weeks, 12 weeks, and 52 weeks from baseline, with imaging in the DaTscan group performed one to four weeks from baseline.

    The results, which were presented at the Movement Disorder Society meeting in Dublin, showed that significantly more patients in the DaTscan imaging group had at least one change in their clinical management from baseline after 12 weeks and after one year, compared with patients in the control group.

    In addition, significantly more DaTscan patients had a change from baseline in diagnosis, and their physicians expressed greater confidence of diagnosis at all visits, compared with physicians of control patients. In the DaTscan group, change in diagnosis at one year was found to be significantly higher among general neurologists (75%) than movement disorder specialists (47%).

    As for side effects, the researchers concluded that DaTscan was well-tolerated, GE said.

    || About || Advertising || || Bookstore || Breast MRI || Career Center || Case of the Day || Communities || Conferences || Contact Us || ECR News 2014 || Education || Equipment Classifieds || Europe || Facebook || Forums || Home || Links || Marketplace || Middle East || Mobile || Molecular Breast Imaging || New Installations || News in Brief || People in the News || Privacy Policy || RSNA News 2013 || Reference || Salary Survey Results || Trends in Radiology || Twitter || Vendor Connect || Webinars || XML/RSS ||

    Copyright © 2014 All Rights Reserved.